Citigroup initiated coverage on 89bio with a new price target
$ETNB
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of 89bio with a rating of Buy and set a new price target of $25.00
Get the next $ETNB alert in real time by email
Get the next $ETNB alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $ETNB
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/14/2025 | $11.00 | Neutral | Goldman |
| 3/13/2025 | $25.00 | Buy | Citigroup |
| 2/4/2025 | Outperform | Wolfe Research | |
| 4/22/2024 | $30.00 | Buy | BofA Securities |
| 1/12/2024 | $24.00 → $15.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 10/10/2023 | Outperform → Perform | Oppenheimer | |
| 8/28/2023 | $36.00 | Buy | UBS |
| 6/13/2023 | $49.00 | Outperform | Evercore ISI |
89bio to Participate in the Leerink Partners Global Healthcare Conference
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible in the investor section of 89bio's website. A replay of the webcast will be available for approximately 30 days following the conference. Abou
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data expected in 1H 2027 and 2028, respectively – –The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) will be unblinded after study completion at Week 52 vs. Week 26 following discussions with the U.S. Food and Drug Administration (FDA); topline data are now expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $440.0 million as of December 31, 2024; a follow-on offering in the 1Q 2025 resulted in gross proceeds of $287.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 163,650 shares of the Company's common stock to seven new employees (the "Inducement Grants") on January 31, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants wer
Goldman initiated coverage on 89bio with a new price target
Goldman initiated coverage of 89bio with a rating of Neutral and set a new price target of $11.00
Citigroup initiated coverage on 89bio with a new price target
Citigroup initiated coverage of 89bio with a rating of Buy and set a new price target of $25.00
Wolfe Research initiated coverage on 89bio
Wolfe Research initiated coverage of 89bio with a rating of Outperform
Director Ra Capital Management, L.P. bought $49,999,994 worth of shares (5,714,285 units at $8.75) (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Director Mcwherter Charles bought $99,850 worth of shares (15,000 units at $6.66), increasing direct ownership by 150% to 25,000 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Chief Executive Officer Palekar Rohan bought $39,450 worth of shares (5,000 units at $7.89), increasing direct ownership by 1% to 471,236 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Officer Le-Nguyen Quoc was granted 14,750 shares and covered exercise/tax liability with 1,050 shares, decreasing direct ownership by 0.30% to 343,652 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Chief Financial Officer Martins Ryan covered exercise/tax liability with 780 shares, decreasing direct ownership by 0.29% to 269,674 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Chief Medical Officer Mansbach Harry H covered exercise/tax liability with 1,050 shares, decreasing direct ownership by 0.33% to 318,834 units (SEC Form 4)
4 - 89bio, Inc. (0001785173) (Issuer)
Amendment: SEC Form SCHEDULE 13D/A filed by 89bio Inc.
SCHEDULE 13D/A - 89bio, Inc. (0001785173) (Subject)
SEC Form S-8 filed by 89bio Inc.
S-8 - 89bio, Inc. (0001785173) (Filer)
SEC Form 10-K filed by 89bio Inc.
10-K - 89bio, Inc. (0001785173) (Filer)
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company. "We are delighted to welcome Dr. Teresa Perney to our executive leadership team at this critical juncture for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance pegozafermin through
89bio Appoints Francis Sarena as Chief Operating Officer
SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024. "We are excited to welcome Francis to our executive team at this pivotal growth phase for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance our Phase 3 clinical program for pegozafermin and prepare for scale up, Francis' extensive strategic, operational, business development and leadership expertise will be immensely valuable. His prov
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
SAN FRANCISCO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Dr. Charles McWherter to its Board of Directors, effective July 30, 2024. Dr. McWherter most recently served as Chief Scientific Officer and President of Research and Development of CymaBay Therapeutics until it was acquired by Gilead Sciences in March 2024. "We are thrilled to welcome Charles, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, CEO of 89bio. "His expertise in drug dev
89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks
- 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0005) - - 30mg QW dose had a placebo-adjusted effect size of 19% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 21% on NASH resolution without worsening of fibrosis (p=0.0009) - - 44mg Q2W and 30mg QW doses had at least one-stage fibrosis improvement without worsening of NASH at 3.5 times placebo rate and NASH resolution without worsening of fibrosis at 12 to 14 times placebo rate - - Every-two-week dose data reinforces pegozafermin's pot
89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy - - Observed significant and potent reductions in atherogenic lipids (non-HDL-C and apo B), liver fat, and improvements in liver enzymes and glycemic control markers - - ENTRIGUE results support 89bio's transition to a late-stage development company; Phase 3 expected to initiate in first half of 2023 - - Conference call and webcast today at 1:30 p.m. PST/4:30 p.m. EST - SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, In
Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 – - Appointment of Rohan Palekar to Board of Directors – - Company to host conference call today, March 1, 2022 at 1:30 p.m. PT / 4:30 p.m. ET – SEATTLE, March 01, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended December 31, 2021.
Amendment: SEC Form SC 13D/A filed by 89bio Inc.
SC 13D/A - 89bio, Inc. (0001785173) (Subject)
Amendment: SEC Form SC 13G/A filed by 89bio Inc.
SC 13G/A - 89bio, Inc. (0001785173) (Subject)
Amendment: SEC Form SC 13G/A filed by 89bio Inc.
SC 13G/A - 89bio, Inc. (0001785173) (Subject)